Request Trial

Biotech news

Reset all filters
Geography
Company
Refine search
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
Americas
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
LSPN experts from Goodwin Law, Invivyd, and New England Biolabs discuss the challenges of patent eligibility under 35 U.S.C. § 101 in life sciences innovation. The session explores strategies to address obstacles arising from recent court decisions and USPTO guidelines.   16 July 2025
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking to Sarah Speight, the pair explain what makes a good IP strategy, why the UPC is largely “useless” without SPCs, and more.   15 July 2025
Explainer: ARIPO’s role in Plant Variety Protection
Africa
Explainer: ARIPO’s role in Plant Variety Protection
Africa’s agricultural future is imperative to life and prosperity in the region—and the Arusha Protocol gives breeders the protection they need, explains the African Regional Intellectual Property Organization.   15 July 2025
Biotech
WATCH: Mastering the art of IP transactions—due diligence, valuation, and deal-making
LSPN brings together experts from Venable, Ipsen, Stoke Therapeutics, and Biogen to analyse best practices for IP transactions, from due diligence and valuation to structuring deals.   8 July 2025
Europe
BMS unit loses cell therapy patent at European Patent Office
Board of Appeal upholds opposition challenge over added subject-matter claims | Dispute concerned patent relating to T cell therapeutic manufacturing methods.   3 July 2025
Americas
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024.   2 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
Judge says sale of genetic data is ‘scary proposition’ but that blanket ban could result in missed opportunities | Former CEO Anne Wojcicki will repurchase business that she co-founded and ran for years.   1 July 2025
Europe
Broad Institute wins appeal to restore CRISPR patent in Europe
Biotech institute successfully challenges EPO decision revoking key CRISPR patent over priority rights | Appeal follows major changes to European law | Case returns to lower court for novelty and inventive step evaluation.   26 June 2025
Americas
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
This panel brings together experts from Wolf Greenfield, BlueRock Therapeutics, BioNTech, and Generate Biomedicines to explore the evolving landscape of pharmaceutical collaborations. The discussion focuses on how partnerships can accelerate drug discovery, share risks, and pool resources in today’s complex drug development environment.   25 June 2025
Americas
Regeneron hits Amgen over its blockbuster eye disease treatment
The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.   19 June 2025